5-Aminoimidazole-4-carboxamide riboside sensitizes TRAIL- and TNFα-induced cytotoxicity in colon cancer cells through AMP-activated protein kinase signaling

Rong-Ying Su, Yee Chao, Tsai-Yu Chen, et al.


Updated Version
Access the most recent version of this article at:
doi:10.1158/1535-7163.MCT-06-0800

Cited Articles
This article cites 44 articles, 17 of which you can access for free at:
http://mct.aacrjournals.org/content/6/5/1562.full.html#ref-list-1

Citing Articles
This article has been cited by 7 HighWire-hosted articles. Access the articles at:
http://mct.aacrjournals.org/content/6/5/1562.full.html#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.
5-Aminoimidazole-4-carboxamide riboside sensitizes TRAIL- and TNFα-induced cytotoxicity in colon cancer cells through AMP-activated protein kinase signaling

Rong-Ying Su,1 Yee Chao,2 Tsai-Yu Chen,1 Duen-Yi Huang,1 and Wan-Wan Lin1

1Department of Pharmacology, College of Medicine, National Taiwan University and 2Cancer Center, Veterans General Hospital, Taipei, Taiwan

Abstract
Death receptor-mediated tumor cell death, either alone or in combination with other anticancer drugs, is considered as a new strategy for anticancer therapy. In this study, we have investigated the effects and molecular mechanisms of 5-aminoimidazole-4-carboxamide riboside [AICAR; a pharmacologic activator of AMP-activated protein kinase (AMPK)] in sensitizing tumor necrosis factor (TNF)–related apoptosis-inducing ligand (TRAIL)– and TNFα-induced apoptosis of human colon cancer HCT116 cells. The cytotoxic action of AICAR requires AMPK activation and may occur at various stages of apoptotic pathways. AICAR cotreatment with either TRAIL or TNFα enhances activities of caspase-8, caspase-9, and caspase-3; down-regulates the antiapoptotic protein Bcl-2; increases the cleavage of Bid and results in the decrease of mitochondrial membrane potential; potentiates activation of p38 and c-Jun NH2-terminal kinase; and inhibits nuclear factor-κB activity. In addition, this sensitized cell apoptosis was neither observed in p53-null HCT116 cells nor affected by the cotreatment with mevalonate. In summary, we have developed a novel strategy of combining AICAR with TRAIL for the treatment of colon cancer cells. The sensitization effect of AICAR in cell apoptosis was mediated through AMPK pathway, requires p53 activity, and involves mitochondria-dependent apoptotic cascades, p38 and c-Jun NH2-terminal kinase. [Mol Cancer Ther 2007;6(5):1562–71]

Introduction
Tumor necrosis factor (TNF)–related apoptosis-inducing ligand (TRAIL), a member of the TNF family, is considered a promising anticancer agent due to its ability to induce apoptosis in a variety of tumor cell types while having only negligible effects on normal cells (1, 2). Sensitivity to TRAIL-induced apoptosis is a key factor influencing the efficacy of TRAIL treatment. Through interaction on death domain-containing receptors [death receptor 4 (DR4) and death receptor 5 (DR5); ref. 3], TRAIL can recruit intracellular adaptor molecule Fas-associated protein with death domain protein (FADD) that engages proximal caspase-8 at the receptor site (4). The activated caspase-8 is released into the cytoplasm and initiates a protease cascade that activates “effector” caspases, such as caspase-3 and caspase-7, thereby triggering the execution steps of apoptosis (extrinsic apoptotic pathway). In addition, active caspase-8 can cleave the proapoptotic Bcl-2 family member Bid generating tBid. tBid in turn translocates to mitochondria and stimulates release of apoptogenic proteins from the mitochondria, thereby amplifying caspase activation (intrinsic apoptotic pathway). In this scenario, the activation of caspase-8, which is considered to be the most apical caspase mediating the extrinsic apoptotic pathway, occurs downstream of effector caspase. Antiapoptotic Bcl-2 family members, such as Bcl-2 and Mcl-1, can support membrane integrity of mitochondria, whereas proapoptotic Bcl-2 family members, such as Bax and Bad, can accelerate intrinsic apoptosis.

AMP-activated protein kinase (AMPK) belongs to a family of serine/threonine protein kinases. The AMPK cascade is a sensor of cellular energy change, which monitors the AMP/ATP ratio to regulate cellular metabolism by restoring ATP levels (5). Several metabolic stresses, including hypoxia, exercise, and long-term starvation, lead to the activation of AMPK (6, 7). 5-Aminoimidazole-4-carboxamide riboside (AICAR) is widely used as a pharmacologic activator of AMPK (5). Although the function of AMPK in metabolism has been well shown, its roles in cell proliferation and cell survival remain poorly documented and somewhat controversial. In agreement with its protective activation from metabolic stresses, AMPK has been proposed as an antiapoptotic molecule to protect cell injury resulting from ischemia (8), hyperglycemia (9), glucose deprivation (10), and ceramide production (11). On the other hand, some reports indicate the ability of AMPK to induce apoptosis of neuroblastoma cells (12, 13), pancreatic cells (14), and gastric cancer cells (15). The latter studies suggest that AMPK signaling might
facilitate growth inhibition and cell killing, serving as a new therapeutic target in cancer diseases (16). Until now, the molecular mechanisms for AMPK-dependent cell arrest and apoptosis remain unclear but might be mediated by up-regulation of p53 and/or inhibition of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase (16). It is likely that the controversial effects of AMPK on cell protection or growth inhibition depend on cell types, cellular events following external stimuli, duration of AMPK activation, and/or downstream-regulated pathways of AMPK.

Given that TRAIL is a promising antitumor agent with no apparent systemic toxicity (17) and that tumor resistance to TRAIL-induced cytotoxicity remains an issue to be solved, recent studies have focused on sensitizing strategy for TRAIL-mediated cancer therapy. Although TNFs cannot be applied in cancer therapy due to marked inflammatory side effects (23), its ability to induce cell death also provides a model to delineate the intracellular inflammatory side effects (23), its ability to induce cell death also provides a model to delineate the intracellular apoptotic machinery. Herein, in this study, we concomitantly used TRAIL and TNFs as cytotoxic inducers to elucidate their combinatorial effects with AICAR on cancer cell viability. Moreover, we explored the molecular mechanisms leading to their interacting outcome. Consequently, we observed that the potentiation of TRAIL- and TNF-induced tumor cell apoptosis by AICAR was dependent on AMPK, p53, involving various aspects of apoptotic pathways, which included the enhancement of Bid degradation, inhibition of Bcl-2 and nuclear factor-κB (NF-κB), loss of mitochondrial membrane potential, and activation of c-Jun NH2-terminal kinase (JNK), p38, and caspases.

Materials and Methods

Reagents

RPMI 1640, fetal bovine serum, penicillin, and streptomycin were obtained from Life Technologies. Polyclonal antibodies against extracellular signal-regulated kinase (ERK) 2, p38 mitogen-activated protein kinase (MAPK), JNK, p65, p50, McI-1L/S (L form and S form), Bcl-2, FADD-like interleukin-1 beta-converting enzyme-like inhibitory protein (FLIP), Bad, Bax, caspase-3, and horseradish peroxidase–coupled antibodies were purchased from Santa Cruz Biotechnology. Bid, caspase-8, caspase-9, AMPKα, poly(ADP-ribose) polymerase, and phosphorylated antibodies of AMPKα, ERK, acetyl-CoA carboxylase α, JNK, ERK, and p38 MAPK were purchased from Cell Signaling. Decoy receptor 2 (Dr2) antibody was purchased from Stressgen. Decoy receptor 1 (Dr1) antibody was purchased from BD PharMingen Technical. U0126, SB203580, and AICAR were purchased from Calbiochem. SP600125 was obtained from Tocris Cookson. Rhodamine-6G was from Sigma. The sequence used to detect the DNA-binding activities of NF-κB was 5′-GATCAGTTGAGGGACTTTCCAGGC-3′. Soluble recombinant human TRAIL was purchased from PeproTech and recombinant TNFa, z-Val-Ala-Asp-floromethylketone (ZVAD-FMK), and Z-Ile-Glu(OMe)-Thr-Asp(OMe)-fluoromethylketone (Z-IETD-FMK) were purchased from R&D Systems.

Cell Culture

Human colon adenocarcinoma HCT116 cells were obtained from the American Type Culture Collection. HCT116 p53−/− cells were kindly provided form Dr. Bert Vogelstein (Howard Hughes Medical Institute and The Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins Medical Institutions, Baltimore, MD). The culture medium used was RPMI 1640, containing 10% fetal bovine serum, 20 mmol/L HEPES buffer, and 100 μg/mL gentamicin. Cells were incubated at 37°C in a humidified atmosphere of 5% CO2 in air.

Measurement of Cell Viability by 3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide Assay

Cell viability was assessed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Cells were resuspended in PBS containing 10% fetal bovine serum, 20 mmol/L HEPES buffer, and 100 μg/mL gentamicin. Cells were incubated at 37°C in a humidified atmosphere of 5% CO2 in air.

Cell Cycle Analysis by Flow Cytometry

Adherent cells after drug treatment were harvested by trypsinization, combined with nonadherent cells, washed twice with PBS, and then fixed with ice-cold 75% ethanol. Cells were resuspended in PBS, and propidium iodide was added and incubated in the dark for 30 min. The samples were analyzed with flow cytometry (Becton Dickinson FACSscan). The sub-G1 peak was quantified and represented the nonviable cell population.

Assessment of Mitochondrial Membrane Potential

Mitochondrial membrane potential (Δψm) was measured by flow cytometry using the rhodamine-123, whose accumulation in the mitochondria of living cells depends on Δψm. For doing this, cells were resuspended in PBS containing 10 μg/mL rhodamine-123 for 15 min at 37°C and then immediately submitted for flow analysis.

Cell Death and Caspase Activity Assay

Cell apoptosis was detected by Cell Death Detection ELISA Plus kit (Roche Diagnostics). Caspase-8 and caspase-3 activities were determined by Colorimetric Assay kits (BioVision). Cell lysates prepared were incubated for 2 h. Thereafter, the absorbance at 405 nm was measured with a spectrophotometer.

Transient Transfection and NF-κB–Dependent Luciferase Assay

Reporter gene containing NF-κB binding sites (pGL2-ELMA-luciferase) and β-galactosidase expression vector
(pCR3lacZ) were prepared using endotoxin-free plasmid preparation kits (Qagen). Cells were seeded into 12-well plates overnight before transfection with 0.25 μg of each plasmid by using LipofectAMINE Plus reagent (Invitrogen).

**Immunoblotting Analysis**

Cell lysates were harvested as described previously (24), and equal amounts of the soluble protein, as determined by the Bradford protein assay, were denatured, subjected to SDS-PAGE, and transferred to nitrocellulose membrane. Specific protein was then detected by antibody followed by chemiluminescence detection reagent (Amersham Biosciences).

**Electrophoretic Mobility Shift Assays**

An electrophoretic mobility shift assay reaction mixture contains 100 mmol/L KCl, 5 μg nuclear protein, 1 μg poly(deoxyinosinic-deoxycytidylic acid), and 10 fmol γ-32P-radiolabeled probe for NF-κB (5'-GATCAGTTGAGGGGACTTTCCCAGGC-3'). In some samples, specific antibodies against p50 and p65 were cotreated to distinguish the action specificity. After incubation for 20 min on ice, reaction mixtures were resolved by 5% native polyacrylamide gel in TBE buffer.

**RNA Interference for AMPK**

AMPKα1 catalytic subunit disruption was achieved by RNA interference using a vector-based small hairpin RNA approach. The target sequence obtained from Dharmacon RNA Technologies was 5'-UUAAGGCUUCAUCAUCAUGGU-3' (order number, 1047752; primer number, PRKAA1-HSS108456). In a control group, small interfering RNA with low guanine cytosine content comparable with that of the functional small interfering RNA but lacking specificity for known gene targets was used. Cells were transfected with small interfering RNAs by using LipofectAMINE 2000 (Invitrogen) following the manufacturer’s instruction.

**Statistical Evaluation**

Values were expressed as the mean ± SE of at least three experiments, which was done in duplicate. ANOVA was used to assess the statistical significance of the differences, and a P value of <0.05 was considered statistically significant.

**Results**

**AICAR Enhances the Apoptotic Effects of TRAIL and TNFα**

As shown in Fig. 1A, cell viability determined by MTT assay was reduced by TRAIL (50, 100, and 200 ng/mL) and TNFα (50 and 100 ng/mL). After 24-h treatment with 200 ng/mL TRAIL and 100 ng/mL TNFα, cell survival was found to be ~70%. However, addition of 1 mmol/L AICAR dramatically enhanced TRAIL and TNFα-induced cell death despite the fact that AICAR alone did not cause cell death.

**Figure 1.** AICAR potentiates the apoptotic effects of TRAIL and TNFα. A, HCT116 colon cancer cells were plated in 96 wells, each well contains 2 x 10⁴ cells and treated with TRAIL or TNFα at the indicated concentrations, with or without AICAR (1 mmol/L) for 24 h, and then we used MTT to assay the viability of HCT116. B, after treating AICAR at different concentrations (0.3, 1, and 3 mmol/L) with TRAIL (50 ng/mL) or TNFα (100 ng/mL) for 24 h, we measured the survival rate by MTT. C, as treated as (B), we used Cell Death Detection assay kits to determine the apoptosis level of cells treated with AICAR alone or in combination with cytokines. D, HCT116 cells were treated with cytokine alone or in combination with AICAR for 12 h. After overnight fixation, we used flow cytometry to determine the sub-G1 peak level. Columns, mean of at least three independent experiments; bars, SE. *, P < 0.05, indicating the significant potentiation of cell response to cytokines by AICAR; **, P < 0.05, indicating significant effects of cytokine and AICAR alone compared with cells without drug treatment.
significant cytotoxicity. Figure 1B showed that AICAR possessed the dose-dependent effects to sensitize cytotoxicity in response to both cytokines after 24-h treatment. Moreover, we used apoptosis assay kits to confirm the dose-dependent effect of AICAR (Fig. 1C). Apoptosis assay was more sensitive than MTT assay, as we observed a slight induction of cell apoptosis by AICAR alone at 1 and 3 mmol/L. Besides using MTT and apoptosis assays, we also did propidium iodide staining to analyze the percentage of cells containing fragmented DNA. As shown in Fig. 1D, treatment of AICAR, TRAIL, or TNFalpha alone slightly increased sub-G1 cell fractions; however, AICAR (1 and 3 mmol/L) cotreatment with TRAIL (50 ng/mL), TNFalpha (100 ng/mL), AICAR (1 mmol/L), or in combination of these agents for 24 h. The survival was determined by MTT assay. Columns, mean of at least three independent experiments; bars, SE. *P < 0.05, indicating the significant potentiation of cytokine-induced caspase activation by AICAR (A and B) or significant inhibition of cytokine-induced cell death by caspase inhibitors (C).

Figure 2. AICAR enhances caspase activation by TRAIL and TNFalpha. Cells were treated with agents as indicated for different time intervals (1, 5, or 9 h), and then cell lysates were collected to determine the caspase-8 (A) and caspase-3 (B) activities. C, cells were pretreated with 30 μmol/L pan-caspase inhibitor (ZVAD-FMK [ZVAD]) or 30 μmol/L caspase-8 inhibitor (Z-IETD-FMK [Z-IETD]) for 1 h followed by treating TRAIL (50 ng/mL), TNFalpha (100 ng/mL), AICAR (1 mmol/L), or in combination of these agents for 24 h. The survival was determined by MTT assay. Columns, mean of at least three independent experiments; bars, SE. *, P < 0.05, indicating the significant potentiation of cytokine-induced caspase activation by AICAR (A and B) or significant inhibition of cytokine-induced cell death by caspase inhibitors (C).
p18), caspase-3 (indicated by the decrease of procaspase-3 level), and cleavage of poly(ADP-ribose) polymerase (as indicated by the decrease of full-length PARP 116 kDa and production of cleaved fragment 89 kDa), the proteolysis of procaspase-9 (as indicated by the decrease of procaspase-9 and appearance of the cleaved active fragments 37/35 kDa) was less apparent. However, in the presence of AICAR, proteolysis of all these proteins was significantly enhanced. Such action of synergism was also observed in cells cotreated with TNFα and AICAR.

Because several apoptotic molecules are involved in mitochondrial integrity and effector caspase activation, we postulated that AICAR promoted cell apoptosis by altering other apoptosis-regulating proteins. As shown in Fig. 3C, AICAR costimulation with cytokines leads to the apparent reduction of Bcl-2 and Bid (proform). Nevertheless, levels of Mcl-1L/FLIP, Bad, and Bax showed no change in combined treatment.

**Roles of MAPKs in AICAR Enhancement of Cell Susceptibility to TRAIL and TNFα**

Because MAPKs play important roles in modulation of apoptosis, we determine if such signaling pathways involve in our study. Consequently, we observed that TRAIL, TNFα, and AICAR alone slightly increased the phosphorylated forms of ERK, JNK, and p38 (Fig. 4A–C).
However, the combination of each cytokine and AICAR resulted in synergistic activation of JNK and p38. Increased ERK activation was less prominent than JNK and p38. Next, we found that SB203580 (a selective inhibitor of p38 MAPK) and SP600125 (a selective inhibitor of JNK) can reverse the enhanced cytokine toxicity induced by AICAR, whereas U0126 (a selective inhibitor of MEK) did not show such activity (Fig. 4D).

**AICAR Inhibits TRAIL- and TNFα-Induced NF-κB Activation**

Another potential mechanism whereby AICAR regulates TRAIL- and TNFα-induced apoptosis was through interaction with the NF-κB/Rel family of transcription factor, whose activity has been reported to prevent apoptosis induced by members of the TNFα family. To test this notion, we first determined NF-κB activity by reporter assay. Figure 5A showed that on cotreating AICAR, which itself had no effect, the increased NF-κB luciferase activities induced by TRAIL and TNFα were almost abrogated. When we harvested nuclear extract to measure the levels of p65, we detected the ability of AICAR to reduce cytokine-induced nuclear translocation of p65 at 1- and 2-h incubation (Fig. 5B). Moreover, DNA-binding activity as examined by electrophoretic mobility shift assay further showed the ability of AICAR to inhibit TRAIL- and TNFα-induced NF-κB activation (Fig. 5C).

**AMPK and p53 Involve in AICAR-Enhanced Apoptosis**

To investigate if AICAR-sensitized apoptosis was mediated through AMPK activation, we first tested whether AICAR can increase the phosphorylated forms of AMPK (an essential step for AMPK activation) and its target substrate (acetyl-CoA carboxylase) in HCT116 cells. Figure 6A revealed the effects of AICAR for inducing AMPK and acetyl-CoA carboxylase phosphorylation. Then, we used small interfering RNA approach specific for AMPKα1 to abolish the function of AMPK. AMPKα1 is the major isoform of AMPKα catalytic subunit in HCT116 cells. Under such treatment for 24 h, the synthesis of AMPKα1 was abolished. Moreover, the subsequent events for AICAR-increased cell apoptosis (Fig. 6B) and caspase-3 activity (Fig. 6C) in response to TRAIL and TNFα were prevented compared with control group.

To determine if p53 might contribute to AMPK-dependent cell apoptosis, we did experiments in p53-null cells. Moreover, as AMPK has been reported to inhibit HMG-CoA reductase, which in turn might contribute to antitumor activity, we addressed this possibility by addition of mevalonate, the direct product of HMG-CoA reductase. As depicted in Fig. 6D, AICAR failed to induce any effect in p53-null cells compared with the sensitized cell death observed in wild-type

---

**Figure 4.** AICAR potentiates TRAIL-activated p38 and JNK. Following stimulations (1 mmol/L AICAR, 50 ng/mL TRAIL, and 100 ng/mL TNFα) for indicated time intervals, cell lysates were used for immunoblotting with antibody specific for phosphorylation or total form of ERK (A), JNK (B), or p38 MAPK (C). In (D), we pretreated cells with SP600125 (10 μmol/L), SB203580 (10 μmol/L), or U0126 (10 μmol/L) for 1 h and then treated with agents as indicated for 24 h. The cell survival was determined by MTT. Columns, mean of at least three independent experiments; bars, SE. *, P < 0.05, indicating the significant reverse of cytokine- plus AICAR-induced cell apoptosis by JNK and p38 inhibitors.
HCT116 cells. However, the presence of mevalonate in WT cells did not affect the sensitized cell death caused by AICAR.

**Discussion**

TRAIL is selectively cytotoxic in inducing tumor cell death and has minimal or no toxicity against normal tissues (17). Thus, TRAIL is a new target with great potential for anticancer treatment, especially in combination with other anticancer therapy. Compared with tumor specificity of TRAIL, the diverse and potent biological actions resulting in inflammation hinder the application of TNFα in tumor therapy (23). Generally, the apoptotic signaling pathways for both death ligands are in common, except the major difference that TRAIL death receptors directly interact with FADD, whereas TRADD is prerequisite to link TNFR1 signaling complex to formation of the FADD-caspase-8 proapoptotic complex. In addition, recruitment of adaptor protein, TNF receptor-associated factor 2, was implicated in TNFR1-induced activation of the antiapoptotic NF-κB pathway, whereas TNF receptor-associated factor 2 was only modestly recruited to TRAIL death receptors. Although no therapeutic intervention, the present study on the combined effect of AICAR and TNFα will provide a useful model system in mechanistic characterization.

Several recent reports showed that AICAR exhibited both antiapoptotic and proapoptotic effects in different cell types (12, 15, 25). Moreover, AICAR was also shown to suppress cell proliferation (16, 26). In our present study, AICAR reduced HCT116 cell viability significantly and in a dose-dependent manner after treating with TRAIL and TNFα. Here, we used different methods to confirm loss of cell viability, such as MTT assay, apoptosis kits, and measurement of sub-G1 content. For mechanistic study, we chose 1 mmol/L AICAR to investigate its sensitization effects on TRAIL and TNFα. At this concentration, neither dramatic cell viability nor G1 cell cycle arrest (data not shown) was caused by AICAR. Previous studies suggest that agents that can arrest cells in the G0-G1 phase may increase TRAIL-induced cytotoxicity (27). Our present data further showed that the potentiation of TRAIL- and TNFα-induced apoptosis by AICAR was mediated by AMPK, as we found that this action of AICAR was diminished in cells under si-AMPKα1 treatment. AMPKα1 is the predominant catalytic subunit of AMPK in HCT116 cells. Moreover, we also ruled out the fact that the sensitization effect of AICAR was associated with the changes in the expression of death receptors and decoy receptors.

Caspase- and mitochondria-mediated apoptosis coordinate in response to a wide range of death stimuli. Both caspase-8–mediated extrinsic apoptotic pathway and tBid-mediated intrinsic apoptotic pathway can contribute in a widely varying degree to death receptor-induced apoptosis. According to the contribution of caspase-8 and tBid stimulation, two response phenotypes of death receptor-induced apoptosis have been defined. In type I cells, caspase-8 is robustly activated and by itself is sufficient to trigger effector caspases to an extent allowing the execution of apoptosis. In contrast, in type II cells, death receptor-induced caspase-8 activation alone is not sufficient.
to activate effector caspases, and under this condition, tBid-initiated release of apoptogenic mitochondrial proteins can make a significant contribution to apoptosis. In this study, the abilities of TRAIL and TNFα in inducing Bid cleavage, indicating the participation of mitochondria-dependent apoptotic machinery in cell death, led to define HCT116 cells as type II cells. In agreement with our current findings, a previous report also corroborated that HCT116 cells behaved as type II cells in response to TRAIL (28).

We have also shown that sensitization of TRAIL- and TNFα-induced cell death by AICAR was preceded by the enhanced Bid down-regulation, loss of mitochondrial membrane potential, caspase-3, caspase-8, and caspase-9 cleavage and caspase activation. In addition, we also have shown that cell death was prevented by inhibitors of caspase-8 (Z-IETD-FMK) and pan-caspase inhibitor (ZVAD-FMK). These results suggested that mitochondrial involvement in AICAR-induced tumor cell susceptibility to TRAIL and TNFα and that the apoptotic pathways triggered by cytokine alone or in combination with AICAR were converged to caspase activation. Here, we also found that compared with TRAIL, the TNFα-activated loss of mitochondrial membrane potential and Bid cleavage were less apparent. These findings suggested that under the tested concentrations of cytokines, intrinsic apoptotic pathway played a minor role in HCT116 cells treated with TNFα compared with TRAIL. One possible mechanism for such differential response might be ascribed to the more prominent effect of TNFα on NF-κB activation than that of TRAIL.

Bcl-2 family was well recognized to regulate intrinsic apoptosis pathway, and some antitumor drugs can induce apoptosis in cancer cells by modulating Bcl-2 protein family. As reported, the antiapoptotic molecules Bcl-2 and FLIP can protect some tumor cell lines from TRAIL-induced apoptosis (29, 30), and proapoptotic molecule Bax was essential for the apoptosis of HCT116 cells after treatment with TRAIL (31). Under these contexts, both antiapoptotic molecules (such as FLIP, Bcl-2, and Mcl-1) and proapoptotic molecules (such as Bid, Bad, and Bax) were examined in this study. Among them, we showed that the presence of AICAR and cytokines could down-regulate Bcl-2 while up-regulating Bid cleavage. Down-regulation of the antiapoptotic Bcl-2 may increase the available concentrations of tBid, leading to a greater release of apoptotic

Figure 6. AICAR enhances cytokine-induced cell apoptosis through AMPK- and p53-dependent pathways. A, cell lysates prepared from cells with AICAR (0.3 and 1 mmol/L) stimulation for 4 h were immunoblotted with antibody specific for phosphorylated (pAMPKα) or total form of AMPKα and phosphorylated (pACC) or total form of acetyl-CoA carboxylase. Traces are representative of three separate experiments. B and C, Cells were transfected with specific si-AMPKα1 small interfering RNA to disturb AMPK function or low guanine cytosine (GC) as described in Material and Methods. Cells were stimulated with agents as indicated for 8 h, and then apoptosis was measured by Cell Death Detection Assay kit (B) and caspase-3 assay kit (C). The transfection efficiency of si-AMPKα1 was verified by immunoblotting (B). In (D), wild-type and p53-null HCT116 cells were treated with AICAR (1 mmol/L) and/or TRAIL (50 ng/mL) for 24 h. Cell viability was determined by MTT assay. In some experiments, wild-type cells were cotreated with mevalonate (200 μmol/L). Columns, mean of at least three independent experiments; bars, SE. *, P < 0.05, indicating the significant inhibition of AICAR potentiation of cytokine-induced cell apoptosis (B), caspase activation (C), or significant enhancement of TRAIL-induced cytotoxicity by AICAR in wild-type cells (D).
proteins from the mitochondria. Activation of p53, a key step for inducing intrinsic apoptosis (32), has been identified to sensitize cancer cell response of TRAIL (33). Because one proposed mechanism for AMPK-mediated antiproliferation was mediated by p53 (16), we examined the role of p53 in AICAR-mediated cell death. Based on results obtained from p53-null HCT116 cells, we showed that AMPK-mediated intrinsic apoptotic sensitization requires p53 activation.

Despite the paucity of information, inhibition of HMG-CoA reductase might contribute to anti-tumor activity (34). In this aspect, HMG-CoA reductase inhibitors (statins) were shown to increase TRAIL-induced cytotoxicity (27). Proposed anti-tumor mechanisms of HMG-CoA reductase inhibition were primarily related to reduced levels of mevalonate and its downstream products (including geranylpyrophosphate and farnesylpyrophosphate), many of which play important roles in cell proliferation and survival (34). AMPK activation has been reported to phosphorylate and inhibit this enzyme and reduce cholesterol levels (16). Here, we showed that cell death-promoting effect of AICAR might not be mediated through the inhibition of HMG-CoA reductase. We have observed that exogenous mevalonate did not overcome the death-inducing effect of AICAR, although it can prevent biological outcome of statins (24, 35).

Contribution of MAPKs in cell apoptosis has been extensively documented. As indicated previously, p38 MAPK and JNK activation lead to mitochondrial apoptotic pathway (36, 37), and JNK activation promotes processing of Bid to proapoptotic cleavage product (38). To date, several studies using pharmacologic or molecular approaches have indicated that AMPK was an upstream regulating molecule for activation of p38 (37, 39, 40), JNK (14, 41), and ERK (42). Our results using selective inhibitors indicated that JNK and p38 contribute to AICAR sensitization of TRAIL- and TNFα-induced apoptosis, and their activities were actually enhanced by the presence of AICAR together with TRAIL and TNFα. We therefore suggest that p38 and JNK may be involved in mitochondrial apoptotic pathway.

NF-κB is widely known for its ubiquitous roles in cell survival and apoptosis (43). NF-κB protects cells from apoptosis by transcriptional activation of survival factors, such as c-FLIP, XIAP, c-IAP, A1, Bcl-2, and Bcl-xL. This ability explains the role of NF-κB as an inhibitor of cell death. Our current data showed that AICAR was able to inhibit NF-κB activity induced by TRAIL and TNFα. This conclusion was supported by immunoblotting, showing the inhibition of p65 nuclear translocation; electrophoretic mobility shift assay, showing the inhibition of DNA binding; and reporter assay, showing the inhibition of transcriptional activity. This inhibition on NF-κB by AICAR was consistent with the previous report in glioblastoma cells (44).

In summary, we showed that AICAR, through AMPK signaling pathway, sensitizes death receptor-mediated cytotoxicity in human colon cancer cells. Enhancement of mitochondria-dependent apoptotic cascades, concomitant sensitization of p38 and JNK activities, and inhibition of NF-κB activity all contributed to the sensitized cytotoxic action of AICAR. This enhanced tumor-directed activity identified AMPK signaling as a potential target for cancer therapeutics, especially in current progress made toward improving the therapeutic efficacy by targeting and activation of death receptors. Another property that might benefit the development of AMPK activator in cancer therapy was the identification of its cytoprotective functions rather than cytotoxicity exerted by AMPK in normal cells that respond to stress.

References


